person · Reporting owner

Lubman Ellen

Disclosed activity across 1 company

Tapewire entity: 84377
SEC CIK: 0001857842

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Werewolf Therapeutics, Inc.HOWL · Entity 7244	Chief Business Officer	January 02, 2025	January 06, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Werewolf Therapeutics, Inc.

Report date January 02, 2025 · Filed January 06, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.56 · Expires 2034-12-31	Direct	131,900	Reported balance After 2025-01-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-01-02 · Grant · Acquired 131,900 · Balance 131,900 F1: The option was granted on January 2, 2025 with a Vesting Commencement Date of January 1, 2025. The shares underlying the option vest in equal monthly installments over four years, with the initial vesting to commence on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2029.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted on January 2, 2025 with a Vesting Commencement Date of January 1, 2025. The shares underlying the option vest in equal monthly installments over four years, with the initial vesting to commence on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2029.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 02, 2025 Filed Jan 6, 2025 22:51 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	GrantStock Option (right to buy) · Derivative	131,900	$0.00 Strike: $1.56	$0.00	Disclosure SEC source: 0000950170-25-002362 · ownership.xml · derivative · entry 1 Lubman Ellen · CIK 0001857842 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,900 Underlying: Common Stock · 131,900 shares Expires 2034-12-31 F1 · derivative.exercise_date: The option was granted on January 2, 2025 with a Vesting Commencement Date of January 1, 2025. The shares underlying the option vest in equal monthly installments over four years, with the initial vesting to commence on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2029. Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:37 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	GrantStock Option (right to buy) · Derivative	131,900	$0.00 Strike: $4.64	$0.00	Disclosure SEC source: 0000950170-24-001956 · ownership.xml · derivative · entry 1 Lubman Ellen · CIK 0001857842 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,900 Underlying: Common Stock · 131,900 shares Expires 2033-12-31 F1 · derivative.exercise_date: The option was granted on January 2, 2024 with a Vesting Commencement Date of January 1, 2024. The shares underlying the option vest in equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2028. Read SEC document
January 03, 2023 Filed Jan 10, 2023 02:36 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	GrantStock Option (right to buy) · Derivative	86,200	$0.00 Strike: $2.05	$0.00	Disclosure SEC source: 0000899243-23-001410 · doc4.xml · derivative · entry 1 Lubman Ellen · CIK 0001857842 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,200 Underlying: Common Stock · 86,200 shares Expires 2032-12-31 F1 · derivative.exercise_date: The option was granted on January 3, 2023 with a Vesting Commencement Date of January 1, 2023. The shares underlying the option vest in equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2027. Read SEC document
January 06, 2022 Filed Jan 18, 2022 23:30 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	GrantStock Option (right to buy) · Derivative	51,088	$0.00 Strike: $11.55	$0.00	Disclosure SEC source: 0000899243-22-002198 · doc4.xml · derivative · entry 1 Lubman Ellen · CIK 0001857842 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,088 Underlying: Common Stock · 51,088 shares Expires 2032-01-05 F1 · derivative.exercise_date: The option was granted on January 6, 2022 with a Vesting Commencement Date of January 1, 2022. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the Vesting Commencement Date and 2.0833% of the shares vesting each month thereafter through January 1, 2026. Read SEC document
April 30, 2021 Filed May 4, 2021 20:30 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	GrantStock Option (right to buy) · Derivative	48,455	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0000899243-21-018108 · doc4.xml · derivative · entry 3 Lubman Ellen · CIK 0001857842 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,455 Underlying: Common Stock · 48,455 shares Expires 2031-04-29 F3 · derivative.exercise_date: The option was granted on April 30, 2021. The shares underlying the option vest over four years in equal monthly installments through April 30, 2025. Read SEC document
December 08, 2020 Filed May 4, 2021 20:30 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	GrantStock Option (right to buy) · Derivative	118,781	$0.00 Strike: $4.77	$0.00	Disclosure SEC source: 0000899243-21-018108 · doc4.xml · derivative · entry 2 Lubman Ellen · CIK 0001857842 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,781 Underlying: Common Stock · 118,781 shares Expires 2030-12-07 F2 · derivative.exercise_date: The option was granted on December 8, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and 2.0833% of the shares vesting each month thereafter through December 8, 2024. Read SEC document
August 03, 2020 Filed May 4, 2021 20:30 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	GrantStock Option (right to buy) · Derivative	145,531	$0.00 Strike: $1.56	$0.00	Disclosure SEC source: 0000899243-21-018108 · doc4.xml · derivative · entry 1 Lubman Ellen · CIK 0001857842 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,531 Underlying: Common Stock · 145,531 shares Expires 2030-08-02 F1 · derivative.exercise_date: The option was granted on August 3, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and 2.0833% of the shares vesting each month thereafter through December 8, 2024. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.